Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Phosphoric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 known ✓ | P52333 | 7/20 | 0.44 |
| ▸ | JAK2 known ✓ | O60674 | 6/20 | 0.44 |
| ▸ | PTK2 | Q05397 | 5/20 | 0.44 |
| ▸ | CFTR | P13569 | 4/20 | 0.43 |
| ▸ | TP53 | P04637 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | CDK4 | P11802 | 4/20 | 0.41 |
| ▸ | CCND1 | P24385 | 3/20 | 0.41 |
| ▸ | CCNB2 | O95067 | 2/20 | 0.41 |
| ▸ | CDK1 | P06493 | 2/20 | 0.41 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.41 |
| ▸ | CCND2 | P30279 | 2/20 | 0.41 |
| ▸ | CCND3 | P30281 | 2/20 | 0.41 |
| ▸ | CCNB3 | Q8WWL7 | 2/20 | 0.41 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.41 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.41 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.41 |
| ▸ | CDK2 | P24941 | 1/20 | 0.41 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3748201 | 0.96 | JAK3 (0.47) | JAK3JAK2PTK2CFTRTP53 | |
| SCHEMBL3749814 | 0.92 | JAK3 (0.45) | JAK3JAK2PTK2CFTRTP53 | |
| SCHEMBL3749379 | 0.87 | JAK2 (0.49) | JAK3JAK2PTK2CDK4CCND1 | |
| SCHEMBL3754995 | 0.79 | MAPK1 (0.47) | JAK3JAK2PTK2CFTRTP53 | |
| SCHEMBL3751156 | 0.78 | MAPT (0.46) | JAK3JAK2PTK2CFTRTP53 | |
| SCHEMBL3750895 | 0.72 | CDK4 (0.51) | TP53MAPTMAPK1CDK4CCND1 | |
| SCHEMBL3757216 | 0.69 | CDK4 (0.48) | TP53MAPTMAPK1CDK4CCND1 | |
| SCHEMBL13048127 | 0.66 | ADORA3 (0.57) | JAK3JAK2TP53MAPTMAPK1 | |
| SCHEMBL12085363 | 0.65 | CDK4 (0.65) | TP53MAPTMAPK1CDK4CCND1 | |
| SCHEMBL13048167 | 0.65 | TP53 (0.48) | JAK3JAK2PTK2TP53MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100298557-A1 | PYRAZOLOPYRIMIDINE COMPOUND | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2010-11-25 | — | — | US | disclosed |
| EP-2123654-A1 | PYRAZOLOPYRIMIDINE COMPOUND | Taisho Pharmaceutical Co. Ltd. (JP) | 2009-11-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298557-A1 | PYRAZOLOPYRIMIDINE COMPOUND | SYK, LCK, FYN | JAK3 58/4885JAK2 13/4885PTK2 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.